161 related articles for article (PubMed ID: 11059749)
1. Silibinin up-regulates insulin-like growth factor-binding protein 3 expression and inhibits proliferation of androgen-independent prostate cancer cells.
Zi X; Zhang J; Agarwal R; Pollak M
Cancer Res; 2000 Oct; 60(20):5617-20. PubMed ID: 11059749
[TBL] [Abstract][Full Text] [Related]
2. Dietary feeding of silibinin inhibits advance human prostate carcinoma growth in athymic nude mice and increases plasma insulin-like growth factor-binding protein-3 levels.
Singh RP; Dhanalakshmi S; Tyagi AK; Chan DC; Agarwal C; Agarwal R
Cancer Res; 2002 Jun; 62(11):3063-9. PubMed ID: 12036915
[TBL] [Abstract][Full Text] [Related]
3. Castration-induced up-regulation of insulin-like growth factor binding protein-5 potentiates insulin-like growth factor-I activity and accelerates progression to androgen independence in prostate cancer models.
Miyake H; Pollak M; Gleave ME
Cancer Res; 2000 Jun; 60(11):3058-64. PubMed ID: 10850457
[TBL] [Abstract][Full Text] [Related]
4. In vivo progression of LAPC-9 and LNCaP prostate cancer models to androgen independence is associated with increased expression of insulin-like growth factor I (IGF-I) and IGF-I receptor (IGF-IR).
Nickerson T; Chang F; Lorimer D; Smeekens SP; Sawyers CL; Pollak M
Cancer Res; 2001 Aug; 61(16):6276-80. PubMed ID: 11507082
[TBL] [Abstract][Full Text] [Related]
5. Suppression of advanced human prostate tumor growth in athymic mice by silibinin feeding is associated with reduced cell proliferation, increased apoptosis, and inhibition of angiogenesis.
Singh RP; Sharma G; Dhanalakshmi S; Agarwal C; Agarwal R
Cancer Epidemiol Biomarkers Prev; 2003 Sep; 12(9):933-9. PubMed ID: 14504208
[TBL] [Abstract][Full Text] [Related]
6. Silibinin strongly synergizes human prostate carcinoma DU145 cells to doxorubicin-induced growth Inhibition, G2-M arrest, and apoptosis.
Tyagi AK; Singh RP; Agarwal C; Chan DC; Agarwal R
Clin Cancer Res; 2002 Nov; 8(11):3512-9. PubMed ID: 12429642
[TBL] [Abstract][Full Text] [Related]
7. Silibinin inhibits renal cell carcinoma via mechanisms that are independent of insulin-like growth factor-binding protein 3.
Cheung CW; Vesey DA; Nicol DL; Johnson DW
BJU Int; 2007 Feb; 99(2):454-60. PubMed ID: 17313429
[TBL] [Abstract][Full Text] [Related]
8. Role of insulin-like growth factor binding proteins in 1alpha,25-dihydroxyvitamin D(3)-induced growth inhibition of human prostate cancer cells.
Stewart LV; Weigel NL
Prostate; 2005 Jun; 64(1):9-19. PubMed ID: 15651061
[TBL] [Abstract][Full Text] [Related]
9. Castration-induced increases in insulin-like growth factor-binding protein 2 promotes proliferation of androgen-independent human prostate LNCaP tumors.
Kiyama S; Morrison K; Zellweger T; Akbari M; Cox M; Yu D; Miyake H; Gleave ME
Cancer Res; 2003 Jul; 63(13):3575-84. PubMed ID: 12839944
[TBL] [Abstract][Full Text] [Related]
10. Silibinin suppresses in vivo growth of human prostate carcinoma PC-3 tumor xenograft.
Singh RP; Deep G; Blouin MJ; Pollak MN; Agarwal R
Carcinogenesis; 2007 Dec; 28(12):2567-74. PubMed ID: 17916909
[TBL] [Abstract][Full Text] [Related]
11. Growth inhibition of breast epithelial cells by celecoxib is associated with upregulation of insulin-like growth factor binding protein-3 expression.
Levitt RJ; Buckley J; Blouin MJ; Schaub B; Triche TJ; Pollak M
Biochem Biophys Res Commun; 2004 Apr; 316(2):421-8. PubMed ID: 15020235
[TBL] [Abstract][Full Text] [Related]
12. Comparative effects of DHEA vs. testosterone, dihydrotestosterone, and estradiol on proliferation and gene expression in human LNCaP prostate cancer cells.
Arnold JT; Le H; McFann KK; Blackman MR
Am J Physiol Endocrinol Metab; 2005 Mar; 288(3):E573-84. PubMed ID: 15536203
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of telomerase activity and secretion of prostate specific antigen by silibinin in prostate cancer cells.
Thelen P; Wuttke W; Jarry H; Grzmil M; Ringert RH
J Urol; 2004 May; 171(5):1934-8. PubMed ID: 15076315
[TBL] [Abstract][Full Text] [Related]
14. Blockade of the type I IGF receptor expression in human prostate cancer cells inhibits proliferation and invasion, up-regulates IGF binding protein-3, and suppresses MMP-2 expression.
Grzmil M; Hemmerlein B; Thelen P; Schweyer S; Burfeind P
J Pathol; 2004 Jan; 202(1):50-9. PubMed ID: 14694521
[TBL] [Abstract][Full Text] [Related]
15. Antiproliferative and apoptotic effects of silibinin in rat prostate cancer cells.
Tyagi A; Bhatia N; Condon MS; Bosland MC; Agarwal C; Agarwal R
Prostate; 2002 Nov; 53(3):211-7. PubMed ID: 12386921
[TBL] [Abstract][Full Text] [Related]
16. Differential regulation of IGFBP-3 by the androgen receptor in the lineage-related androgen-dependent LNCaP and androgen-independent C4-2 prostate cancer models.
Kojima S; Mulholland DJ; Ettinger S; Fazli L; Nelson CC; Gleave ME
Prostate; 2006 Jun; 66(9):971-86. PubMed ID: 16541420
[TBL] [Abstract][Full Text] [Related]
17. Insulin-like growth factor binding protein-3 induces early apoptosis in malignant prostate cancer cells and inhibits tumor formation in vivo.
Devi GR; Sprenger CC; Plymate SR; Rosenfeld RG
Prostate; 2002 May; 51(2):141-52. PubMed ID: 11948969
[TBL] [Abstract][Full Text] [Related]
18. Up-regulation of insulin-like growth factor-binding protein 3 by 5-fluorouracil (5-FU) leads to the potent anti-proliferative effect of androgen deprivation therapy combined with 5-FU in human prostate cancer cell lines.
Kawabata R; Oie S; Takahashi M; Kanayama H; Oka T; Itoh K
Int J Oncol; 2011 Jun; 38(6):1489-500. PubMed ID: 21455575
[TBL] [Abstract][Full Text] [Related]
19. The therapeutic and preventive effect of RRR-alpha-vitamin E succinate on prostate cancer via induction of insulin-like growth factor binding protein-3.
Yin Y; Ni J; Chen M; DiMaggio MA; Guo Y; Yeh S
Clin Cancer Res; 2007 Apr; 13(7):2271-80. PubMed ID: 17404112
[TBL] [Abstract][Full Text] [Related]
20. Increased insulin-like growth factor I receptor expression and signaling are components of androgen-independent progression in a lineage-derived prostate cancer progression model.
Krueckl SL; Sikes RA; Edlund NM; Bell RH; Hurtado-Coll A; Fazli L; Gleave ME; Cox ME
Cancer Res; 2004 Dec; 64(23):8620-9. PubMed ID: 15574769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
